Could a higher dose of TB drug save kids with HIV?
NCT ID NCT05069688
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a higher dose of the TB medicine rifampicin is safe and works well in children with both HIV and TB. Twenty children will take their usual HIV and TB drugs, but for two weeks the rifampicin dose will be increased. Researchers will measure drug levels in the blood to see if the higher dose improves treatment without causing harm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rifampicin and dolutegravir
What this could lead to
If successful, this could lead to safer and more effective TB treatment for children with HIV, potentially shortening therapy duration.
What could go wrong
This is a very small early-phase study with only 20 children, so results may not apply broadly. High-dose rifampicin could also cause side effects or drug interactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College Hospital/ University of Ibadan
RECRUITINGIbadan, Oyo State, Nigeria
Contact